One-year Results After Single-center Water Vapor Thermal Therapy for Symptomatic Benign Prostatic Hyperplasia.

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

71 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-01-01

Study Completion Date

2023-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Objective: Rezūm vapor ablation is a minimally invasive treatment for benign prostatic hyperplasia (BPH) that uses injections of sterile water vapor directly into the prostate for tissue ablation. Although Rezūm is currently indicated for use in men with prostate sizes ≥30 and ≤80 ml, it is unclear how effective Rezūm is for men in urinary retention. The investigators sought to determine whether Rezūm is effective in the treatment of catheter-dependent urinary retention secondary to BPH.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Optimized Water Vapor Thermal Therapy for Benign Prostatic Hyperplasia

NCT06607094

Benign Prostatic Hyperplasia

NOT_YET_RECRUITING NA

Comparing Water Vapour Thermal Therapy (Rezūm) and TURP

NCT05762198

Prostate Cancer

RECRUITING NA

Rezum for 30-80ml Patients With Moderate-severe LUTS to Study Surgical Principles for Median Lobe Enlargement

NCT06177821

Prostatic Hyperplasia of the Medial Lobe

RECRUITING NA

Comparing Rezum and Urolift

NCT06820606

Prostate Cancer

RECRUITING NA

Local Anesthesia With Schelin Catheter in Rezum Treatment: a Randomized Controlled Trial

NCT06657872

Benign Prostatic Hyperplasia

RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The data of participants who underwent Rezūm operation with the diagnosis of BPH between 2021 and 2023 were evaluated retrospectively. The investigators evaluated procedure details and evaluated pre- and post-Rezūm (including International Prostate Symptom Score (IPSS), IPSS quality of life (IPSS-QOL), prostate volumes, maximum flow (Qmax), post-void residual urine volume, IEEF-5, ejaculation dysfunction). The investigators examined variables at 6 and 12 months).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Prostatic Hyperplasia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

singel

REZUM

Intervention Type DEVICE

The 3rd and 12th month follow-ups of the patients who underwent REZUM operation were evaluated.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

REZUM

The 3rd and 12th month follow-ups of the patients who underwent REZUM operation were evaluated.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

-Benign prostatic hyperplasia

Exclusion Criteria

* Prostate cancer
* Parkinson's disease,
* Neurogenic bladder
* Overactive bladder
* Bladder calculus,
* Bladder Tumor
* Urinary infection
* Alzheimer's disease

Minimum Eligible Age

40 Years

Maximum Eligible Age

100 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes